Daiichi Sankyo : Submits Supplemental Application in Japan for Approval of Partial Changes in Usage or Dosage for Anticoagulant Edoxaban

Tokyo - Daiichi Sankyo Company Limited (hereinafter, Daiichi Sankyo) announced today that it submitted an supplemental application in Japan for an expanded approved usage or dosage for the anticoagulant, edoxaban, for elderly patients with non-valvular atrial fibrillation and high bleeding risk.

This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation therapies.

Daiichi Sankyo expects to contribute to the treatment of elderly patients with non-valvular atrial fibrillation by providing the new treatment option.

Contact:

Junichi Onuma

Tel: [phone]

Web: https://www.daiichisankyo.com

(C) 2020 Electronic News Publishing, source ENP Newswire